Epitopea Doses First Patient in Phase 1/1b Trial for Advanced Ovarian Cancer

  • First patient dosed in OVACT Phase 1/1b trial of CryptiVax™-1001 for advanced high-grade serous ovarian cancer (HGSOC).
  • Trial will enroll up to 30 patients across 10 UK clinical centers.
  • CryptiVax™-1001 targets HRP+/BRCA-wildtype HGSOC, an underserved patient population.
  • Epitopea's CryptoMap™ platform identifies novel tumor-specific antigens from the 'dark genome'.
  • Trial led by Professor Susana Banerjee of The Royal Marsden and ICR.

Epitopea's trial initiation highlights the growing focus on RNA-based immunotherapies for solid tumors, particularly in indications with limited durable treatment options. The company's CryptoMap™ platform represents a novel approach to identifying tumor-specific antigens, potentially expanding the reach of personalized cancer vaccines. Success in this trial could validate Epitopea's technology and position it as a key player in the oncology immunotherapy space.

Clinical Efficacy
Whether CryptiVax™-1001 demonstrates meaningful durable responses in HRP+/BRCA-wildtype HGSOC patients.
Regulatory Pathway
The pace at which Epitopea advances through clinical phases given the trial's design and patient population.
Competitive Positioning
How Epitopea's off-the-shelf RNA vaccine approach differentiates it in the crowded ovarian cancer treatment landscape.